Tumor suppressor p53 plays a crucial role in carcinogenesis and chemosensitivity, and it is also mutated in a majority of malignant diseases, including colorectal cancer (Hollstein et al., 1991) . Several clinical and experimental trials have shown the inactivation of p53 to be correlated with resistance to chemotherapy in colorectal cancers (Lowe et al., 1994; Bunz et al., 1999) . p53 is a transcriptional factor, which induces its target genes, such as p21, Bax, Noxa, and Puma, to regulate either cell cycle arrest or apoptosis in response to chemotherapeutic drugs (el-Deiry et al., 1993; Miyashita and Reed, 1995; Vogelstein et al., 2000; Oda et al., 2000; Yu et al., 2003) . Since the inactivation of p53 target gene, Bax or Puma, also promotes resistance to chemotherapy in colorectal cancer cells (Zhang et al., 2000; Yu et al., 2003) , the status of p53 target genes should be assessed as well as p53, when considering the use of chemotherapy for the treatment of colorectal cancer. We previously reported apoptosis-associated speck-like protein containing the caspase recruitment domain (CARD), ASC, to be a p53 target gene, which plays an important role in p53-mediated apoptosis (Ohtsuka et al., 2004) . ASC is an unusual adaptor protein that consists of an amino-terminal Pyrin domain followed by calboxy-terminal CARD (Masumoto et al., 1999) . ASC interacts with Bax through the Pyrin domain to regulate Bax translocation to the mitochondria, thus resulting in mitochondrial permiabilization, cytochrome c release, and activation of caspase-9 and -3 (Ohtsuka et al., 2004) . ASC is also known as TMS1 (target gene of methylation-induced silencing-1), and inactivated in 40% of breast cancer and 50% of melanoma (Conway et al., 2000; Guan et al., 2003) . Although the significance of methylation-induced ASC silencing remains obscure, the methylation of ASC might cause resistance to anticancer drugs in colorectal cancer, the same as in other p53 target genes. If this is the case, then the gene introduction of ASC would increase chemosensitivity, and thus become a new treatment strategy for colorectal cancers. The aims of this study were to investigate the frequency of methylation of ASC in patients with colorectal cancer, and to clarify the effect of the expression of ASC on p53-mediated chemosensitivity in colon cancer cells.
To study the potential role of ASC silencing in pathogenesis of colorectal cancer, we established the methylation status of the ASC gene in normal mucosa and colorectal cancer patient samples. Figure 1a shows the methylation status of the CpG island of ASC in 16 Japanese patients with colorectal cancer, who underwent curative resection at our institution between 1998 and 2003. The methylation of ASC in cancer lesions was detected in four patients (25%, Nos. 9, 10, 14, and 16), while in two patients, ASC was methylated in the normal mucosa (Nos. 2 and 9). The expression of ASC protein and the patients' profiles are summarized in Figure 1b . The expression levels of ASC protein varies and absence of expression was observed in two patients (Nos. 14 and 15), in which ASC was methylated. A p53 mutation was found in three patients (19%). Two of them showed a mutation of G to A in codon 175 (Nos. 4 and 15), and another one of G to A in codon 161 (No. 3). The methylation of ASC and p53 mutation thus seemed to occur independently. Three of four patients with methylated-ASC showed well-differentiated adenocarcinoma, while the remaining showed melanoma. All four patients with ASC methylation had no lymph node metasitasis (Duke's A or B), and did not receive adjuvant chemotherapy. Therefore, we cannot determine the significance of ASC methylation in chemosensitivity in patients with colorectal cancer.
To clarify our hypothesis, we used colon cancer cells and investigated the role of ASC in p53-dependent chemosensitivity. SW48 cells have wild-type p53 but lack ASC expression (Figure 2a and b) . CW2 colon cancer cells thus served as positive controls for both ASC expression and induction in response to wild-type p53 accumulation. When treated with 5-Aza deoxycytidine, an inhibitor of DNA metyltransferase, ASC expresseion was restored in response to 5-fluorouracil (5-FU) in SW48 cells (Figure 2c ). These data suggest that methylation is the cause of ASC suppression in SW48 cells. SW48 cells were infected with adenovirus expressing myc-tagged ASC (Ad-ASC), or green fluorescent protein (Ad-GFP) as a control (Ohtsuka et al., 2004) , at two different ASC expression levels (5 and 20 moi). At 24 h after infection, the cells were treated with 5-FU and then were incubated for an additional 24 h. All cells were collected and subjected to Western blotting and Trypan blue staining. A low expression of ASC itself was insufficient to trigger cell death; however, the sensitivity to 5-FU increased from 14 to 22% under this expression level of ASC (Figure 2d) . A high expression of ASC induced significant cell death by itself (17%), and further increased chemosensitivity to 30% (Figure 3d ).
We next used HCT116 colon cancer cell lines with or without wild-type 53, which were generous gifts from Dr B Vogelstein at Johns Hopkins University (Bunz et al., 1999) , to confirm the role of ASC in p53-dependent chemosensitivity. As shown in Figure 3a and b, HCT116 cells had no trace of ASC expression regardless of p53 status. MCF7 breast cancer cells were used as a positive control for the normal expression of ASC. HCT116 p53 cells were infected with either Ad-ASC (5 moi) or Ad-GFP and treated with 5-FU. ASC induction was not observed even after the 5-FU treatment in HCT116 cells regardless of the status of p53 (Figure 3c ). The expression of ASC caused the population of 5-FUinduced dead cell death to increase from 10 to 17% in p53 ( þ / þ ) cells, while it did not promote any significant cell death under these conditions in HCT 116 p53 (À/À) cells (Figure 3c ). These data strongly suggest that ASC is involved in the p53-dependent chemosensitivity in colon cancer cells.
In addition, we investigated the effect of ASC on various kinds of anticancer drug-induced chemosensitivity to clarify the utility of ASC as a gene therapy. HCT 116 p53 ( þ / þ ) cells were infected with either Ad-GFP or Ad-ASC (20 moi), and then were treated with mitomycin C, actinomycin D, doxorubicin, or etoposide. The cells were collected and then subjected to Western blotting and flow cytometry. All four drugs activated p53 (Figure 4a ). The expression of ASC itself caused significant cell death and enhanced the chemosensitivity after treatment with mitomycin C, doxorubicin, and etoposide. On the other hand, actinomycin D had a strong anticancer effect even without ASC, and The resected specimens of cancerous lesions (C) and its adjacent normal mucosa (N) were subjected to two-step methylation-specific polymerase chain reaction (PCR), as previously reported (Herman et al., 1996) . The primers used were 5 0 -GGGGTTTTAATTTAGAGGTTTGGG -3 0 and 5 0 -CCGAC-CATCTCCTACAAACCCATA-3 0 for the first reaction. The secondary primers were 5 0 -CGATTTTGGCGTTTTTC-GACGGTT-3 0 and 5 0 -CCGCTCACCCCGCTACAACCGC-3 0 for the methylation reaction, and 5 0 -TTGTTGGAGGGTAATG-GATT-3 0 and 5 0 -ATACCCACATAAAACACCC-3 0 for the unmethylated reaction. The PCR protocols were 40 cycles of a 30 s deneturation step at 961C, a 30 s annealing step at 601C and a 30 s extension step at 721C for the first reaction, and 25 cycles of the same steps for the second reaction. The unmethylated (U) and methylated (M) bands were shown. Methylation of the CpG island of ASC promoter region was observed in cancer lesions of the patient Nos. 9, 10, 14, and 16. (b) The expression of ASC protein and the pathological features of the 16 patients with colorectal cancer. Protein extractions obtained from 16 cancer lesions were subjected to Western blotting using antibodies against ASC and bactin (internal control). The patients' characters are also summarized. Absence of the expression of the ASC protein was observed in patient Nos. 14 and 16. The tissue samples were also analysed for gene mutations at exons 5-8 of p53, according to the previous protocol (Scarpa et al., 1993) . *C, cecum; A ascending colon; T, transverse colon; D, descending colon; S, sigmoid colon; R, rectum; # W, well-differentiated adenocarcinoma; M, moderately differentiated adenocarcinoma; P, poorly differentiated adenocarcinoma; Me; melanoma.
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T Ohtsuka et al the expression of ASC had a minimal effect on actinomycin D-mediated cell death (Figure 4a ). Tumor suppressor p53 is frequently inactivated in colorectal cancer. In this case, the expression of p53 as well as ASC might have a significant effect of cell death. To clarify this hypothesis, HCT 116 p53 (À/À) cells were infected Ad-GFP, Ad-ASC (20 moi), and/or Ad-p53 (5 moi), and then were collected at 24 and 48 h after infection. The collected cells were subjected to Western blotting and flow cytometry. The expressions of p53 and The methylation of ASC in SW48 colon cancer cells. Genomic DNA was extracted from SW48 cells and the methylation status of ASC was determined by methylation-specific PCR, as described in Figure 1 . ASC was partially methylated in CW2 cells. (c) The restored expression of ASC protein in SW48 treated with inhibitor of methyltransferase. The SW48 cells were treated with 5-Aza deoxycytidine at two different concentrations (0.2 or 2 mM) for 48 h, and then were exposed to 500 mM of 5-FU for additional 24 h. The expression of ASC and the accumulation of p53 were analysed by Western blotting using antibodies against ASC, p53, and b-actin. (d) The expression of ASC enhances the cell death response to 5-FU in SW48 cells. SW48 cells were infected with Ad-ASC at two different ASC expression levels (5 moi, 1 þ , and 20 moi, 4 þ ). At 24 h after infection, the cells were exposed to 500 mM of 5-FU for an additional 24 h. Thereafter, any dead cells were counted by Trypan blue staining, and all stained cells were counted as dead. All experiments were repeated three times, and the value was expressed as the mean7s.d.. Western blotting was also performed using antibodies against myc (ASC), p53, and b-actin. , 1 þ ) . At 24 h after infection, the cells were treated with 5-FU (500 mM) and then were incubated for an additional 24 h. Thereafter, any dead cells were counted by Trypan blue staining, and all stained cells were counted as dead. Experiments were repeated three times, and the value was expressed as the mean7s.d. Western blotting was also performed using antibodies against ASC, p53, and b-actin.
ASC are shown in Figure 4b . The expression of either p53 or ASC caused a significant degree of cell death in HCT 166 p53 (À/À) (about 20%), and combination of p53 and ASC expressions increased the percentage of the cell death to 40% (Figure 4b ). These data implicated that ASC might be used for the treatment of colorectal cancer with the combination of chemotherapeutic drug or p53-gene therapy, according to the p53 status.
There are two principal apoptotic pathways, namely the intrinsic mitochondrial and extrinsic death receptor pathways. p53 can regulates both of them, however, p53-mediated chemotherapeutic regulation is thought to depend on the mitochondrial pathway (Green and Reed, 1999) . Previous reports have demonstrated that a disruption of such mitochondrial proteins as Bax, Puma, or Ferredoxin reductase cause resistance to 5-FU in colon cancer cells (Zhang et al., 2000; Hwang et al., 2001; Yu et al., 2003) . We previously reported ASC to be a key regulator of Bax translocation to the mitochondria and cytochrome c release, which are the critical steps of the p53-mitochondrial apoptotic pathway (Ohtsuka et al., 2004) . We also showed that the suppression of ASC by small interfering RNA prevented Bax translocation and reduced the apoptotic response to anticancer drug in a p53-dependent manner (Ohtsuka et al., 2004) . In this study, we show that the forced expression of ASC promotes cell death and increases chemosensitivity in colon cancer cells. Our data suggested that ASC gene therapy may thus become a new treatment strategy for colorectal cancer. In the case of p53 mutation as well as ASC deficient, combination of the p53 gene therapy might increase the treatment efficacy. All five chemotherapeutic drugs used in this study were found to activate p53. Among them, actinomycin D did not seem to require ASC to regulate p53-mediated cell death. Actinomycin D might regulate the ASC-independent pathway; however, we cannot recommend using this drug for patients with ASCinactivated tumor because this study was based on in vitro study and the effect of anticancer drug depends on the cell type or another gene abnormalities. In fact, actinomycin D is not presently accepted as a treatment for patients with colorectal cancer. However, these data provide us with the possibility that the establishment of a new drug which regulates the ASC-independent pathway may become another potentially useful treatment strategy for colorectal cancer, which is independent of ASC activation.
Genetic and epigenetic modulations of apoptotic genes affect the development, carcinogenesis, tumor growth, chemoradiosensitivity, and inflammatory response. Modulation by the aberrant methylation of CpG islands is a well-characterized epigenetic mechanism, and the methylation-induced silencing of ASC has been observed in several kinds of tumor (Conway et At 24 h after infection, the cells were treated with mitomycin C (MMC, 10 mg/ml), actinomycin D (Act D, 100 ng/ml), doxorubicin (Dox, 600 ng/ml), or etoposide (Eto, 50 mM), and then were incubated for an additional 24 h. Cells were collected and subjected to Western blotting using antibodies against p53 and b-actin, and to flow cytometry to measure the sub-G1 population, which indicates the fraction of cell death. Experiments were repeated three times, and the value was expressed as the mean7s. , 2003) . In this study, the methylation of ASC was observed in four of 16 patients (25%) with colorectal cancer; however, the expression of ASC protein was found in two of these four patients. This same finding that ASC methylation does not always correspond to a lack of ASC protein, has also been observed in a previous report . One possible explanation for this is the heterozygosity of cells; there are cells expressing and non-expressing ASC in cancer lesions, or there exists another mechanism for the expression of ASC, despite the methylation of its promoter region. In addition, a variety of expression levels of ASC protein, as seen in Figure 1a , might be caused by circumstances around the cells, because ASC can be induced by various kinds of stimulation, including p53 activation (Stehlik et al., 2002; Ohtsuka et al., 2004) . The significance of ASC suppression in patients with malignant diseases has not yet been well documented. Since ASC-deficient mice were born and grew normally and had no cancer development, it is suspected that ASC suppression might thus correlate with neither normal development nor carcinogenesis (Mariathasan et al., 2004) . We speculated that the absence of ASC might cause resistance to p53-mediated chemosensitivity based on the findings of our in vitro experiments. On the other hand, we could not determine the significance of ASC suppression by in vivo data, because three of four patients with methylated ASC were in an early stage and they did not receive chemotherapy. Further investigations using a largesized population are thus necessary to clarify this hypothesis.
In conclusion, our data suggest the methylationinduced silencing of ASC might cause some resistance to p53-mediated cell death and the gene introduction of ASC would thereby increase chemosensitivity. This modality may therefore be a potentially useful new treatment strategy for the treatment of colorectal cancer.
